First-in-Human cancer drug trial seeks to tame tough lymphoma

NCT ID NCT06189391

Summary

This is the first study to test a new immunotherapy drug called MK-1045 in people. The goal is to find a safe dose and see if it can help patients with B-cell non-Hodgkin lymphoma that has come back or stopped responding to other treatments. Researchers will give the drug to about 100 participants and closely monitor how their bodies handle it and if their cancer shrinks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer hospital ( Site 0001)

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

    Contact Phone: •••-•••-••••

  • Fifth Medical Center of PLA General Hospital ( Site 0005)

    RECRUITING

    Beijing, Beijing Municipality, 100071, China

    Contact Phone: •••-•••-••••

  • Fudan University Shanghai Cancer Center ( Site 0012)

    RECRUITING

    Shanghai, Shanghai Municipality, 200030, China

    Contact Phone: •••-•••-••••

  • Henan Cancer Hospital ( Site 0009)

    RECRUITING

    Zhengzhou, Henan, 450000, China

    Contact Phone: •••-•••-••••

  • Jiangxi Cancer Hospital ( Site 0007)

    RECRUITING

    Nanchang, Jiangxi, 330029, China

    Contact Phone: •••-•••-••••

  • Shandong Cancer Hospital ( Site 0008)

    ACTIVE_NOT_RECRUITING

    Jinan, Shandong, 250117, China

  • Shanghai East Hospital ( Site 0002)

    RECRUITING

    Shanghai, Shanghai Municipality, 200120, China

    Contact Phone: •••-•••-••••

  • Sichuan Cancer Hospital. ( Site 0018)

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-••••

  • Sun Yat-Sen University Cancer Center ( Site 0003)

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-••••

  • The First Affiliated Hospital of Xiamen University ( Site 0011)

    RECRUITING

    Xiameng, Fujian, 361000, China

    Contact Phone: •••-•••-••••

  • The First Affiliated Hospital of Zhengzhou University ( Site 0006)

    RECRUITING

    Zhengzhou, Henan, 451161, China

    Contact Phone: •••-•••-••••

  • The First Hospital Of Jilin University ( Site 0014)

    RECRUITING

    Changchun, Jilin, 130021, China

    Contact Phone: •••-•••-••••

  • The Fourth Hospital of Hebei Medical University. ( Site 0004)

    RECRUITING

    Shijiazhuang, Hebei, 050035, China

    Contact Phone: •••-•••-••••

  • Tianjin Medical University Cancer Institute and Hospital ( Site 0010)

    ACTIVE_NOT_RECRUITING

    Tianjinc, Tianjin Municipality, 300060, China

  • Zhongshan Hospital,Fudan University ( Site 0013)

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.